Loading
Showed that whole-exome sequencing of blood can track how a cancer evolves, and co-founded Inivata.
Nitzan Rosenfeld led the 2013 Nature study showing that exome sequencing of circulating tumour DNA tracks the evolution of resistance across multiple cancers, and the earlier work using tagged-amplicon sequencing to monitor breast cancer, both foundational to liquid biopsy. He developed methods for detecting ctDNA at very low fractions and co-founded Inivata, now part of NeoGenomics. He moved from Cambridge to Barts in 2023.
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute, Whole-exome & whole-genome sequencing and the tag genomics.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares MRD / molecular residual disease testing, Liquid biopsy (ctDNA) and the tag ctdna.
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute, Whole-exome & whole-genome sequencing and the tag genomics.
Shares Whole-exome & whole-genome sequencing, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Whole-exome & whole-genome sequencing, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA) and the tag ctdna.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, MRD / molecular residual disease testing, Liquid biopsy (ctDNA) and the tag ctdna.